CYP2D6 and cancer: This is similar to a study by Andreassen et al. comparing CYP2D6 PMs, EMs, and UMs within a large cancer cohort on oxycodone, who found no differences in pain intensity, nausea, tiredness, and cognitive function between these groups [21].